SCHEMBL18220149

SCHEMBL18220149

COCCNC(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCN(C)CC4)ccc3c2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.44
OPRM1 P35372 3/20 0.42
OPRD1 P41143 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPKAPK2 P49137 1/20 0.41
APAF1 O14727 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PRKD1 Q15139 2/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 2/20 0.39
MAPT P10636 2/20 0.39
RAD52 P43351 1/20 0.39
RXFP1 Q9HBX9 2/20 0.39
CSF1R P07333 3/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220147 0.93 APP (0.43) APPMEN1KMT2AMAPKAPK2SMN1; SMN2
SCHEMBL18220144 0.92 ALDH1A1 (0.46) APPMEN1KMT2AMAPKAPK2SMN1; SMN2
SCHEMBL19293974 0.85 MAPT (0.43) APPMEN1KMT2AMAPKAPK2SMN1; SMN2
SCHEMBL18220261 0.85 OPRM1 (0.40) APPOPRM1OPRD1MEN1KMT2A
SCHEMBL17120664 0.85 OPRM1 (0.40) APPOPRM1OPRD1MEN1KMT2A
SCHEMBL18219989 0.84 APP (0.49) APPMEN1KMT2APRKD1HPGD
SCHEMBL18220206 0.84 APP (0.44) APPMEN1KMT2APRKD1ALDH1A1
SCHEMBL18220189 0.83 APP (0.43) APPMEN1KMT2APRKD1ALDH1A1
SCHEMBL18220142 0.83 ALDH1A1 (0.58) APPMEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL18220148 0.83 APP (0.43) APPOPRM1OPRD1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885OPRM1 4421/4885OPRD1 4497/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885OPRM1 4377/4885OPRD1 4481/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885OPRM1 4421/4885OPRD1 4497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.